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Reactivation of  
Bovine Tuberculosis   
in Patient Treated 
with Infliximab, 
Switzerland
To  the  Editor:  Increased  risk 
for reactivation of tuberculosis (TB) 
after  treatment  with  tumor  necrosis 
factor (TNF) antagonists, particularly 
infliximab,  is  well  documented  (1). 
We describe a case of peritoneal TB, 
probably  resulting  from  reactivation 
of Mycobacterium bovis infection af-
ter infliximab treatment. In retrospect, 
reactivation might have been prevent-
able had physicians been aware of the 
patient’s history of regularly drinking 
fresh cow’s milk from a local farm in 
Switzerland  during  1944–45,  when 
bovine TB was prevalent.
The  patient  was  a  69-year-old 
Swiss woman who was examined for 
weakness,  abdominal  pain,  increas-
ing abdominal girth, and weight loss 
in April 2008. Her history included a 
diagnosis  of  Crohn  disease  in  1978 
and  treatment  with  glucocorticoids, 
cyclosporine,  and  mercaptopurine. 
In  November  2007,  during  a  recur-
rence of Crohn disease and while re-
ceiving  treatment  with  azathioprine, 
the patient had a negative interferon 
gamma  release  assay  (IGRA)  result 
(QuantiFERON-TB in Tube test; Cell-
estis International, Carnegie, Victoria, 
Australia) and an unremarkable chest 
radiograph. On November 30, 2007, 
she  was  given  prednisone  (40  mg/d 
for  2  weeks,  then  tapered)  and  pre-
scribed 3 doses of infliximab because 
of  severe  inflammation  seen  during 
colonoscopy (5 mg/kg on November 
30, 2007, January 4, 2008, and Febru-
ary 15, 2008). She was hospitalized on 
April 25, 2008, at which time she had 
ascites; the fluid contained 1.4 × 109/L 
leukocytes  (79.5%  lymphocytes)  but 
was negative for acid-fast bacilli on 
direct examination and PCR testing for 
Mycobacterium tuberculosis complex. 
Laparoscopy on May 2, 2008, showed 
extensive  peritoneal  inflammation. 
Peritoneal  biopsy  samples  contained 
acid-fast bacilli and caseating granu-
lomas; PCR for M. tuberculosis com-
plex was positive. At this time, results 
of a repeat QuantiFERON-TB in Tube 
test and a tuberculin skin test (TST) 
were negative, but a T-SPOT.TB (Ox-
ford Immunotec, Abingdon, UK) test 
was  positive  (6-kDa  early  secretory 
antigenic target [ESAT-6], >20 spots; 
10-kDa culture filtrate protein [CFP-
10], 11 spots). M. bovis ssp. bovis was 
grown in cultures of peritoneal biopsy 
samples. For culture, the MGIT 960 
automated  culture  system  (Becton 
Dickinson,  Sparks,  MD,  USA)  was 
used.  The  isolate  was  identified  by 
use of a multiplex PCR-based, solid-
phase,  reverse-hybridization  assay 
(GenoType MTBC, Hain Lifescience 
GmbH, Nehren, Germany), excluding 
M.  bovis  BCG  (2). The  patient  was 
discharged May 30, 2008. In January 
2009,  she  was  much  improved  after 
treatment  with  isoniazid/rifampin/
ethambutol  for  3  months  and  moxi-
floxacin/rifampin for 5 months.
This case of presumed reactiva-
tion of peritoneal TB caused by M. 
bovis in a patient treated with inflix-
imab highlights the need to be aware 
of  local  epidemiology  with  regard 
to  transmissible  infectious  diseases. 
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It  particularly  emphasizes  the  value 
of  careful  history  taking  regarding 
consumption  of  unpasteurized  dairy 
products  in  assessing  risk  for  latent 
TB  infection  (LTBI)  before  starting 
anti-TNF treatment. Some infectious 
diseases experts (3) recommend con-
sidering  LTBI  treatment  before  pre-
scribing anti-TNF therapy even when 
TST  is  negative  or  only  minimally 
positive (<5 mm induration) for pa-
tients with epidemiologic or clinical 
hints of LTBI. This case indicates that 
this  recommendation  should  be  ex-
tended to assessment of the probabil-
ity of latent M. bovis infection. This 
decision may not be easy, and refer-
ral to a TB specialist should be con-
sidered. Excluding LTBI on the basis 
of a negative TST result or IGRA is 
problematic  because  of  the  limited 
sensitivity  of  these  tests,  especially 
for  immunosuppressed  patients  (4). 
Of note, the antigens used in IGRAs 
are  present  in  M.  bovis.  Discordant 
TST and IGRA results are frequent, 
and  these  differences  are  not  easily 
explained  (4).  However,  IGRAs  are 
not confounded by prior vaccination 
with M. bovis BCG, and the T-SPOT.
TB  test  may  have  a  higher  sensi-
tivity  than  QuantiFERON-TB  and 
QuantiFERON-TB  Gold  tests  (Cell-
estis International) (5,6). Our patient 
had a positive T-SPOT.TB result and 
negative QuantiFERON-TB and TST 
results at the time of her diagnosis of 
peritoneal TB.
Recently, another case of perito-
neal TB due to M. bovis in a patient 
treated with infliximab was reported in 
Denmark. This patient’s exposure pre-
sumably consisted of consumption of 
unpasteurized milk at a dairy (7). Tu-
berculosis cases caused by M. bovis are 
probably underreported because many 
laboratories determine only whether a 
pathogen belongs to M. tuberculosis 
complex. In the United States, geno-
typing of culture-confirmed M. tuber-
culosis  complex  has  been  routinely 
done only since 2004 (8).
Our patient probably acquired M. 
bovis infection by frequent consump-
tion of unpasteurized milk in a rural 
area of Switzerland during the 1940s. 
Infection  by  the  respiratory  route  is 
conceivable but unlikely. As the pa-
tient traveled rarely, and only in indus-
trialized countries, more recent trans-
mission of M. bovis seems unlikely. 
According to the requirements of sec-
tion 3.2.3.10 of the World Organisa-
tion  for Animal  Health  International 
Animal Health Code, Switzerland has 
officially  been  free  from  bovine TB 
since 1959. The last sporadic case oc-
curred in 2003, although eradication 
has not been achieved in all neighbor-
ing European countries (9). Of note, in 
the United States and Canada, where 
M. bovis has been virtually eliminated 
in cattle (10), M. bovis infection con-
tinues to be diagnosed today, particu-
larly in children of Hispanic origin and 
those born outside the United States. 
The principal infection route may be 
consumption  of  unpasteurized  dairy 
products from Mexico (8). Awareness 
of the epidemiology of bovine TB and 
careful history taking regarding recent 
or distant (in countries where M. bovis 
infection in cattle has been eradicated) 
consumption  of  unpasteurized  dairy 
products may prompt preventive che-
motherapy before the start of anti-TNF 
treatment. Thus, a potentially increas-
ing number of human TB cases due to 
M. bovis may be prevented.
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